Most of the mild to moderate Alzheimer’s patients enrolled in the atuzaginstat (COR388) Phase 2/3 trial show evidence of systemic infection due to Porphyromonas gingivalis, a bacteria linked to periodontal disease whose toxic enzymes are thought to contribute to Alzheimer’s and are targets for this candidate therapy. A “high proportion” also test positive for biomarkers associated with this neurodegenerative disease. As such, these adults have a profile that supports a response to atuzaginstat’s use in the ongoing GAIN study (NCT03823404),…
You must be logged in to read/download the full post.
The post Gum Disease Bacteria Found in Most Alzheimer’s Patients in Atuzaginstat Trial appeared first on BioNewsFeeds.